Successful treatment of a chronic myeloid leukemia patient with extreme thrombocytosis by a combination of imatinib and interferon‑α: A case report

Jia,Meng-Xiao; Di,Da-Lin; Liu,Zhen-Zhen; Wang,Hai-Ying; Chen,Lei

doi:10.3892/etm.2025.12800

Successful treatment of a chronic myeloid leukemia patient with extreme thrombocytosis by a combination of imatinib and interferon‑α: A case report

Authors:
- Meng-Xiao Jia
- Da-Lin Di
- Zhen-Zhen Liu
- Hai-Ying Wang
- Lei Chen
View Affiliations

Affiliations: Department of Hematology, Affiliated Hospital of Shandong Second Medical University, Weifang, Shandong 261031, P.R. China, Department of Immunology, Shandong Second Medical University, Weifang, Shandong 261053, P.R. China
Published online on: January 16, 2025 https://doi.org/10.3892/etm.2025.12800
Article Number: 50
Copyright: © Jia et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Chronic myeloid leukemia with extreme thrombocytosis (CML‑T), defined by a platelet count >1,000x10⁹/l is a rare leukemia subtype. The present case report described a 66‑year‑old female CML‑T patient presenting with a platelet count of 3,798x10⁹/l, but a consistently normal spleen size. Following treatment with imatinib combined with interferon‑α, the patient achieved hematological remission within 2 months, with a platelet count reduction to 311x10⁹/l and complete cytogenetic remission after 10 months. The patient experienced myocardial infarction and liver injury during treatment, which was managed with supportive care. The present case suggested that imatinib combined with interferon‑α may be a safe and effective treatment option for patients with CML‑T and extreme thrombocytosis and suboptimal response to imatinib monotherapy.

View Figures

View References

1	Jabbour E and Kantarjian H: Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring. Am J Hematol. 95:691–709. 2020.PubMed/NCBI View Article : Google Scholar
2	Rinaldi I and Winston K: Chronic myeloid leukemia, from pathophysiology to treatment-free remission: A narrative literature review. J Blood Med. 14:261–277. 2023.PubMed/NCBI View Article : Google Scholar
3	Osman AEG and Deininger MW: Chronic myeloid leukemia: Modern therapies, current challenges and future directions. Blood Rev. 49(100825)2021.PubMed/NCBI View Article : Google Scholar
4	Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka HM, Wang SA, Bagg A, Barbui T, Branford S, et al: International consensus classification of myeloid neoplasms and acute leukemias: Integrating morphologic, clinical and genomic data. Blood. 140:1200–1228. 2022.PubMed/NCBI View Article : Google Scholar
5	Thakral B, Saluja K, Malhotra P, Sharma RR, Marwaha N and Varma S: Therapeutic plateletpheresis in a case of symptomatic thrombocytosis in chronic myeloid leukemia. Ther Apher Dial. 8:497–499. 2004.PubMed/NCBI View Article : Google Scholar
6	Ebrahem R, Ahmed B, Kadhem S and Truong Q: Chronic myeloid leukemia: A case of extreme thrombocytosis causing syncope and myocardial infarction. Cureus. 8(e476)2016.PubMed/NCBI View Article : Google Scholar
7	Turakhia SK, Murugesan G, Cotta CV and Theil KS: Thrombocytosis and STAT5 activation in chronic myelogenous leukaemia are not associated with JAK2 V617F or calreticulin mutations. J Clin Pathol. 69:713–719. 2016.PubMed/NCBI View Article : Google Scholar
8	Chiatamone Ranieri S, Arleo MA, Trasarti S, Bizzoni L, Carmosino I, De Luca ML, Mohamed S, Mariggiò E, Scalzulli E, Rosati S, et al: Clinical and prognostic features of essential thrombocythemia: Comparison of 2001 WHO Versus 2008/2016 WHO criteria in a large single-center cohort. Clin Lymphoma Myeloma Leuk. 21:e328–e333. 2021.PubMed/NCBI View Article : Google Scholar
9	Haznedaroglu IC: The therapeutic goals of essential thrombocythemia under the clouds of over-treatment and under-treatment. Expert Opin Pharmacother. 14:1431–1436. 2013.PubMed/NCBI View Article : Google Scholar
10	Verma SP, Subbiah A, Jacob SE and Basu D: Chronic myeloid leukaemia with extreme thrombocytosis. BMJ Case Rep. 2015(bcr2014204564)2015.PubMed/NCBI View Article : Google Scholar
11	Talpaz M: Interferon-alfa-based treatment of chronic myeloid leukemia and implications of signal transduction inhibition. Semin Hematol. 38 (Suppl 8):S22–S27. 2001.PubMed/NCBI View Article : Google Scholar
12	Palandri F, Castagnetti F, Iacobucci I, Martinelli G, Amabile M, Gugliotta G, Poerio A, Testoni N, Breccia M, Bocchia M, et al: The response to imatinib and interferon-alpha is more rapid than the response to imatinib alone: A retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase. Haematologica. 95:1415–1419. 2010.PubMed/NCBI View Article : Google Scholar
13	Liu Z, Fan H, Li Y and Liu C: Analysis of clinical characteristics and efficacy of chronic myeloid leukemia onset with extreme thrombocytosis in the era of tyrosine kinase inhibitors. Onco Targets Ther. 10:3515–3520. 2017.PubMed/NCBI View Article : Google Scholar
14	Tefferi A and Barbui T: Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management. Am J Hematol. 95:1599–1613. 2020.PubMed/NCBI View Article : Google Scholar
15	Jang MA and Choi CW: Recent insights regarding the molecular basis of myeloproliferative neoplasms. Korean J Intern Med. 35:1–11. 2020.PubMed/NCBI View Article : Google Scholar
16	Byun YJ, Park BB, Lee ES, Choi KS and Lee DS: A case of chronic myeloid leukemia with features of essential thrombocythemia in peripheral blood and bone marrow. Blood Res. 49:127–129. 2014.PubMed/NCBI View Article : Google Scholar
17	Hiruma K, Saitoh H, Someya K and Kashimura M: Hematologic abnormalities in a patient with chronic myelogenous leukemia with advanced myelofibrosis were improved by G-CSF. Rinsho Ketsueki. 35:135–141. 1994.PubMed/NCBI(In Japanese).
18	Shah NP: Front-line treatment options for chronic-phase chronic myeloid leukemia. J Clin Oncol. 36:220–224. 2018.PubMed/NCBI View Article : Google Scholar
19	Granatowicz A, Piatek CI, Moschiano E, El-Hemaidi I, Armitage JD and Akhtari M: An overview and update of chronic myeloid leukemia for primary care physicians. Korean J Fam Med. 36:197–202. 2015.PubMed/NCBI View Article : Google Scholar
20	Rajabto W and Angkasa YK: Asymptomatic chronic-phase chronic myeloid leukemia BCR-ABL. (+) without splenomegaly: A case report. Niger J Clin Pract. 25:373–375. 2022.PubMed/NCBI View Article : Google Scholar
21	Galvez C and Stein BL: Thrombocytosis and thrombosis: Is there really a correlation? Curr Hematol Malig Rep. 15:261–267. 2020.PubMed/NCBI View Article : Google Scholar
22	Zheng Y, Wen J and Li J: Pediatric chronic myeloid leukemia presenting with extreme thrombocytosis and acute upper gastrointestinal hemorrhage: A case report. J Pediatr Hematol Oncol. 43:e1049–e1051. 2021.PubMed/NCBI View Article : Google Scholar
23	Turroni S, Tolomeo M, Mamone G, Picariello G, Giacomini E, Brigidi P, Roberti M, Grimaudo S, Pipitone RM, Di Cristina A and Recanatini M: A natural-like synthetic small molecule impairs bcr-abl signaling cascades and induces megakaryocyte differentiation in erythroleukemia cells. PLoS One. 8(e57650)2013.PubMed/NCBI View Article : Google Scholar
24	Thiele J, Kvasnicka HM, Varus E, Ollig E, Schmitt-Graeff A, Staib P and Griesshammer M: Megakaryocyte features and bcr/abl translocation in chronic myeloid leukemia following imatinib mesylate (STI571) therapy-a fluorescence in-situ hybridization study. Leuk Lymphoma. 45:1627–1631. 2004.PubMed/NCBI View Article : Google Scholar
25	ten Bosch GJ, Kessler JH, Blom J, Joosten AM, Gambacorti-Passerini C, Melief CJ and Leeksma OC: BCR-ABL oncoprotein is expressed by platelets from CML patients and associated with a special pattern of CrkL phosphorylation. Br J Haematol. 103:1109–1115. 1998.PubMed/NCBI View Article : Google Scholar
26	Bennour A, Ouahchi I, Achour B, Zaier M, Youssef YB, Khelif A, Saad A and Sennan H: Analysis of the clinico-hematological relevance of the breakpoint location within M-BCR in chronic myeloid leukemia. Med Oncol. 30(348)2013.PubMed/NCBI View Article : Google Scholar
27	Arana-Trejo RM, Ruíz Sánchez R, Ignacio-Ibarra G, Báez de la Fuente E, Garces O, Gómez Morales E, Castro Granados M, Ovilla Martínez R, Rubio-Borja ME, Solís Anaya L, et al: BCR/ABL p210, p190 and p230 fusion genes in 250 Mexican patients with chronic myeloid leukaemia (CML). Clin Lab Haematol. 24:145–150. 2002.PubMed/NCBI View Article : Google Scholar
28	Polampalli S, Choughule A, Negi N, Shinde S, Baisane C, Amre P, Subramanian PG, Gujral S, Prabhash K and Parikh P: Analysis and comparison of clinicohematological parameters and molecular and cytogenetic response of two Bcr/Abl fusion transcripts. Genet Mol Res. 7:1138–1149. 2008.PubMed/NCBI View Article : Google Scholar
29	Al-Achkar W, Moassass F, Youssef N and Wafa A: Correlation of p210 BCR-ABL transcript variants with clinical, parameters and disease outcome in 45 chronic myeloid leukemia patients. J BUON. 21:444–449. 2016.PubMed/NCBI
30	Pane F, Mostarda I, Selleri C, Salzano R, Raiola AM, Luciano L, Saglio G, Rotoli B and Salvatore F: BCR/ABL mRNA and the P210(BCR/ABL) protein are downmodulated by interferon-alpha in chronic myeloid leukemia patients. Blood. 94:2200–2207. 1999.PubMed/NCBI
31	Junmei Z, Fengkuan Y, Yongping S, Baijun F, Yuzhang L, Lina L and Qinglan Z: Coexistence of P190 and P210 BCR/ABL transcripts in chronic myeloid leukemia blast crisis resistant to imatinib. Springerplus. 4(170)2015.PubMed/NCBI View Article : Google Scholar
32	Zhang X, Sun H, Su Y and Yi H: Long-term molecular remission after treatment with imatinib in a chronic myeloid leukemia patient with extreme thrombocytosis harboring rare e14a3 (b3a3) BCR::ABL1 transcript: A case report. Curr Oncol. 29:8171–8179. 2022.PubMed/NCBI View Article : Google Scholar
33	Puil L, Liu JX, Gish G, Mbamalu G, Bowtell D, Pelicci PG, Arlinghaus R and Pawson T: Bcr-Abl oncoproteins bind directly to activators of the Ras signalling pathway. EMBO J. 13:764–773. 1994.PubMed/NCBI View Article : Google Scholar
34	Liu RY, Fan C, Garcia R, Jove R and Zuckerman KS: Constitutive activation of the JAK2/STAT5 signal transduction pathway correlates with growth factor independence of megakaryocytic leukemic cell lines. Blood. 93:2369–2379. 1999.PubMed/NCBI
35	Verma D, Kantarjian HM, Jones D, Luthra R, Borthakur G, Verstovsek S, Rios MB and Cortes J: Chronic myeloid leukemia (CML) with P190 BCR-ABL: Analysis of characteristics, outcomes and prognostic significance. Blood. 114:2232–2235. 2009.PubMed/NCBI View Article : Google Scholar
36	Melo JV: BCR-ABL gene variants. Baillieres Clin Haematol. 10:203–222. 1997.PubMed/NCBI View Article : Google Scholar
37	Balatzenko G, Guenova M, Stoimenov A, Jotov G and Toshkov S: Philadelphia chromosome-positive chronic myeloid leukemia with p190(BCR-ABL) rearrangement, overexpression of the EVI1 gene and extreme thrombocytosis: A case report. Cancer Genet Cytogenet. 181:75–77. 2008.PubMed/NCBI View Article : Google Scholar
38	Adnan-Awad S, Kim D, Hohtari H, Javarappa KK, Brandstoetter T, Mayer I, Potdar S, Heckman CA, Kytölä S, Porkka K, et al: Characterization of p190-Bcr-Abl chronic myeloid leukemia reveals specific signaling pathways and therapeutic targets. Leukemia. 35:1964–1975. 2021.PubMed/NCBI View Article : Google Scholar
39	Gleissner B, Gökbuget N, Bartram CR, Janssen B, Rieder H, Janssen JW, Fonatsch C, Heyll A, Voliotis D, Beck J, et al: Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: A prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis. Blood. 99:1536–1543. 2002.PubMed/NCBI View Article : Google Scholar
40	Qiu LL, Lu YJ, Jing Y, Yu L, Liu DH and Wang LL: Comparison of clinical outcomes between P190 and P210 trans-cripts in adult Ph chromosome positive acute lymphoblastic leukemia in the new Era of TKI. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 24:369–374. 2016.PubMed/NCBI View Article : Google Scholar : (In Chinese).
41	Vasconcelos AP, Azevedo IF, Melo FCBC, Neves WB, Azevedo ACAC and Melo RAM: BCR-ABL1 transcript types showed distinct laboratory characteristics in patients with chronic myeloid leukemia. Genet Mol Res. 16:2017.PubMed/NCBI View Article : Google Scholar
42	Guglielmelli P and Calabresi L: The MPL mutation. Int Rev Cell Mol Biol. 365:163–178. 2021.PubMed/NCBI View Article : Google Scholar
43	Stockklausner C, Duffert CM, Cario H, Knöfler R, Streif W and Kulozik AE: THROMKID-Plus Studiengruppe der Gesellschaft für Thrombose-und Hämostaseforschung (GTH) and of Gesellschaft für Pädiatrische Onkologie und Hämatologie (GPOH). Thrombocytosis in children and adolescents-classification, diagnostic approach and clinical management. Ann Hematol. 100:1647–1665. 2021.PubMed/NCBI View Article : Google Scholar
44	Rottenstreich A and Bussel JB: Treatment of immune thrombocytopenia during pregnancy with thrombopoietin receptor agonists. Br J Haematol. 203:872–885. 2023.PubMed/NCBI View Article : Google Scholar
45	Rubenstein AI, Pierson SK, Shyamsundar S, Bustamante MS, Gonzalez MV, Milller ID, Brandstadter JD, Mumau MD and Fajgenbaum DC: Immune-mediated thrombocytopenia and IL-6-mediated thrombocytosis observed inidiopathic multicentric Castleman disease. Br J Haematol. 204:921–930. 2024.PubMed/NCBI View Article : Google Scholar
46	Wolfe HR and Rein LAM: The evolving landscape of frontline therapy in chronic phase chronic myeloid leukemia (CML). Curr Hematol Malig Rep. 16:448–454. 2021.PubMed/NCBI View Article : Google Scholar
47	Flynn JP and Gerriets V: Imatinib. In: StatPearls. StatPearls Publishing, Treasure Island, FL, 2025.
48	Gao L, Ren MQ, Tian ZG, Peng ZY, Shi G and Yuan Z: Management of chronic myeloid leukemia presenting with isolated thrombocytosis and complex Philadelphia chromosome: A case report. Medicine (Baltimore). 100(e27134)2021.PubMed/NCBI View Article : Google Scholar
49	Repsold L, Pool R, Karodia M, Tintinger G, Becker P and Joubert AM: Apoptotic profiling of chronic myeloid leukaemia patients' platelets ex vivo before and after treatment with Imatinib. Cell Biochem Funct. 39:562–570. 2021.PubMed/NCBI View Article : Google Scholar
50	Sener Y, Okay M, Aydin S, Buyukasik Y, Akbiyik F and Dikmen ZG: TKI-related platelet dysfunction does not correlate with bleeding in patients with chronic phase-chronic myeloid leukemia with complete hematological response. Clin Appl Thromb Hemost. 25(1076029619858409)2019.PubMed/NCBI View Article : Google Scholar
51	Shu LL, Jiang QL, Meng FY and Yang M: Molecular mechanism of imatinib-induced thrombocytopenia in treatment of patients with CML. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 19:1314–1318. 2011.PubMed/NCBI(In Chinese).
52	Repsold L, Pool R, Karodia M, Tintinger G and Joubert AM: Ex vivo platelet morphology assessment of chronic myeloid leukemia patients before and after Imatinib treatment. Microsc Res Tech. 85:2222–2233. 2022.PubMed/NCBI View Article : Google Scholar
53	Akram AM, Iqbal Z, Akhtar T, Khalida AM, Sabar MF, Qazi MH, Azize Z, Sajid N, Aleem A, Rasoolh M, et al: Presence of novel compound BCR-ABL mutations in late chronic and advanced phase imatinib sensitive CML patients indicates their possible role in CML progression. Cancer Biol Ther. 18:214–221. 2017.PubMed/NCBI View Article : Google Scholar
54	Al-Ali HK, Heinrich MC, Lange T, Krahl R, Mueller M, Müller C, Niederwieser D, Druker BJ and Deininger MW: High incidence of BCR-ABL kinase domain mutations and absence of mutations of the PDGFR and KIT activation loops in CML patients with secondary resistance to imatinib. Hematol J. 5:55–60. 2004.PubMed/NCBI View Article : Google Scholar
55	Tanaka R and Kimura S: Abl tyrosine kinase inhibitors for overriding Bcr-Abl/T315I: From the second to third generation. Expert Rev Anticancer Ther. 8:1387–1398. 2008.PubMed/NCBI View Article : Google Scholar
56	Dhillon S: Olverembatinib: First approval. Drugs. 82:469–475. 2022.PubMed/NCBI View Article : Google Scholar
57	Binzaid AA, Baqal OJ, Soheib M, Nahedh MA, Samarkandi HH and Aljurf M: Cardiovascular toxicity associated with tyrosine kinase inhibitor therapy in chronic myeloid leukemia. Gulf J Oncolog. 1:79–84. 2021.PubMed/NCBI
58	Caocci G, Mulas O, Annunziata M, Luciano L, Abruzzese E, Bonifacio M, Orlandi EM, Albano F, Galimberti S, Iurlo A, et al: Long-term mortality rate for cardiovascular disease in 656 chronic myeloid leukaemia patients treated with second- and third-generation tyrosine kinase inhibitors. Int J Cardiol. 301:163–166. 2020.PubMed/NCBI View Article : Google Scholar
59	Robak T: Use of interferon in the treatment of chronic myeloproliferative disorders. Acta Haematol Pol. 23 (2 Suppl 1):S30–S37. 1992.PubMed/NCBI(In Polish).
60	Talpaz M, Mercer J and Hehlmann R: The interferon-alpha revival in CML. Ann Hematol. 94 (Suppl 2):S195–S207. 2015.PubMed/NCBI View Article : Google Scholar
61	Kujawski LA and Talpaz M: The role of interferon-alpha in the treatment of chronic myeloid leukemia. Cytokine Growth Factor Rev. 18:459–471. 2007.PubMed/NCBI View Article : Google Scholar
62	Seewann HL: Interferon therapy in essential thrombocythemia. Wien Med Wochenschr. 143:420–424. 1993.PubMed/NCBI(In German).
63	Koike G, Otsuka T, Shibuya T and Niho Y: Thrombocytosis in chronic myelogenous leukemia (CML) controlled by interferon alpha (IFN-alpha). Rinsho Ketsueki. 30:400–403. 1989.PubMed/NCBI(In Japanese).
64	Thiele J, Zirbes T, Kvasnicka HM, Niederle N, Dammasch J, Schmidt M, Windecker R, Leder LD, Diehl V and Fischer R: Interferon therapy, but not busulfan restores normal-sized megakaryopoiesis in CML-a comparative histo- and immunomorphometric study. Anal Cell Pathol. 11:31–42. 1996.PubMed/NCBI
65	Kong J, Qin YZ, Zhao XS, Hou Y, Liu KY, Huang XJ and Jiang H: Profiles of NK cell subsets are associated with successful tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia and changes following interferon treatment. Ann Hematol. 100:2557–2566. 2021.PubMed/NCBI View Article : Google Scholar
66	Rüdiger H, andreas H and Michele B: European LeukemiaNet. Chronic myeloid leukaemia. Lancet. 370:342–350. 2007.PubMed/NCBI View Article : Google Scholar
67	Gabriele L, Borghi P, Rozera C, Sestili Pandreotti M, Guarini A, Montefusco E, Foà R and Belardelli F: IFN-alpha promotes the rapid differentiation of monocytes from patients with chronic myeloid leukemia into activated dendritic cells tuned to undergo full maturation after LPS treatment. Blood. 103:980–987. 2004.PubMed/NCBI View Article : Google Scholar
68	Simonsson B, Gedde-Dahl T, Markevärn B, Remes K, Stentoft J, Almqvist A, Björeman M, Flogegård M, Koskenvesa P, Lindblom A, et al: Combination of pegylated IFN-α2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia. Blood. 118:3228–3235. 2011.PubMed/NCBI View Article : Google Scholar
69	McGlave P, Mamus S, Vilen B and Dewald G: Effect of recombinant gamma interferon on chronic myelogenous leukemia bone marrow progenitors. Exp Hematol. 15:331–335. 1987.PubMed/NCBI
70	Foon KA, Sherwin SA, Abrams PG, Stevenson HC, Holmes P, Maluish AE, Oldham RK and Herberman RB: A phase I trial of recombinant gamma interferon in patients with cancer. Cancer Immunol Immunother. 20:193–197. 1985.PubMed/NCBI View Article : Google Scholar
71	Dou XL, Wang SS, Fang JL, Yu L, Ren X, Huang XJ and Jiang Q: Hepatic adverse events associated with tyrosine kinase inhibitors in patients with chronic myeloid leukemia. Zhonghua Nei Ke Za Zhi. 57:649–655. 2018.PubMed/NCBI View Article : Google Scholar : (In Chinese).
72	O'Brien S, Kantarjian H and Talpaz M: Practical guidelines for the management of chronic myelogenous leukemia with interferon alpha. Leuk Lymphoma. 23:247–252. 1996.PubMed/NCBI View Article : Google Scholar